Le Lézard
Classified in: Health, Covid-19 virus
Subjects: AVO, CPG, CMG, CFG

CMA CALLING FOR RAPID ACTION, GREATER COLLABORATION AND CLEARER COMMUNICATION IN FACE OF COVID-19


OTTAWA, ON, Jan. 11, 2022 /CNW/ - The Canadian Medical Association (CMA) is appealing to federal, provincial and territorial governments to work together to minimize the impact of the current wave of COVID-19 using the tools, experience, and expertise gained from the last two years of the pandemic. The CMA is concerned that the latest wave coursing through the country may leave the health system unable to recover.

"We have gone back in time to overwhelmed hospitals, cancelled surgeries and testing. Most schools across the country are closed for in-person learning, and there is a growing labour shortage. Health care workers have reached the limit of burnout and exhaustion," says Dr. Katharine Smart, CMA President. "We must now double down on using tools and experience to blunt the impact of Omicron and plan for future waves."

The CMA believes Canada can mitigate the pandemic by: 

"We know Canadians are tired and frustrated. Physicians, nurses, respiratory therapists, pharmacists, laboratory technologists and other health care providers are beyond exhausted right now. And we need all hands-on deck to stabilize our health system to care for COVID patients and all others requiring care," says Dr. Smart.

About the CMA
The Canadian Medical Association is the national voice of the medical profession. Our focus is on creating strong and accessible health systems, fostering well-being and diversity in medical culture, and ensuring every person in Canada has equal opportunity to be healthy. In partnership with physicians, medical learners, patients and others, we advance these goals through advocacy, knowledge sharing and granting.

SOURCE Canadian Medical Association


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: